Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Atkins

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanomaJ A Sparano, R I Fisher, M Sunderland, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.
Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1996
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimeraE G Trehu, J W Mier, J S Dubois, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaM J Hawkins, M B Atkins, J P Dutcher, et al.
Cancer Treatment Reviews|June 1, 1989
Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanomaM Sznol, J P Dutcher, M B Atkins, et al.
British Journal of Cancer|January 17, 2013
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenograftsX Wang, L Zhang, A O'Neill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanomaJ A Sparano, R I Fisher, M Sunderland, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.
Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1996
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimeraE G Trehu, J W Mier, J S Dubois, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaM J Hawkins, M B Atkins, J P Dutcher, et al.
Cancer Treatment Reviews|June 1, 1989
Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanomaM Sznol, J P Dutcher, M B Atkins, et al.
British Journal of Cancer|January 17, 2013
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenograftsX Wang, L Zhang, A O'Neill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.
Pageof 11